menu
    • menu
    [{"orgOrder":0,"company":"Geistlich Pharma","sponsor":"Geistlich Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Geistlich Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Geistlich Pharma \/ Geistlich Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Geistlich Pharma \/ Geistlich Pharma"},{"orgOrder":0,"company":"Geistlich Pharma","sponsor":"Geistlich Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"BRAZIL","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Toluidine Blue","moa":"DNA","graph1":"Dental and Oral Health","graph2":"Undisclosed","graph3":"Geistlich Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Geistlich Pharma \/ Geistlich Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Geistlich Pharma \/ Geistlich Pharma"},{"orgOrder":0,"company":"Geistlich Pharma","sponsor":"Translational Drug Development","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Misetionamide","moa":"GAPDH||LPS","graph1":"Oncology","graph2":"Phase I","graph3":"Geistlich Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Geistlich Pharma \/ Translational Drug Development","highestDevelopmentStatusID":"6","companyTruncated":"Geistlich Pharma \/ Translational Drug Development"},{"orgOrder":0,"company":"Geistlich Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"SWITZERLAND","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Taurolidine","moa":"Cell wall","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Geistlich Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Geistlich Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Geistlich Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Geistlich Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"SWITZERLAND","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Taurolidine","moa":"Cell wall","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Geistlich Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Geistlich Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Geistlich Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Geistlich Pharma","sponsor":"Geistlich Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"ITALY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Deproteinized Bovine Bone","moa":"Hydroxylapatite","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Geistlich Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Geistlich Pharma \/ Geistlich Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Geistlich Pharma \/ Geistlich Pharma"},{"orgOrder":0,"company":"Geistlich Pharma","sponsor":"Geistlich Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ISRAEL","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Geistlich Bio-Oss","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Geistlich Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Geistlich Pharma \/ Geistlich Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Geistlich Pharma \/ Geistlich Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Geistlich Pharma

    Menu

    Geistlich Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Geistlich Pharma

                            Switzerland arrow
                            AAPS
                            Not Confirmed

                            Geistlich Pharma

                            Switzerland arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hyaluronic Acid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Recipient : Queen Mary University of London

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hyaluronic Acid and Polynucleotides for Supra-bony Defects

                            Details : Hyaluronic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Periodontal Diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 13, 2024

                            Lead Product(s) : Hyaluronic Acid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Recipient : Queen Mary University of London

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Geistlich Pharma

                            Switzerland arrow
                            AAPS
                            Not Confirmed

                            Geistlich Pharma

                            Switzerland arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Taurolidine

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Trial to Evaluate Safety, Tolerability, Efficacy of PerioSept® as Adjunct to SRP in Subjects With Periodont...

                            Details : PerioSept (Taurolidine) is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Periodontitis.

                            Product Name : PerioSept

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            September 18, 2019

                            Lead Product(s) : Taurolidine

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Geistlich Pharma

                            Switzerland arrow
                            AAPS
                            Not Confirmed

                            Geistlich Pharma

                            Switzerland arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Misetionamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Translational Drug Development

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine

                            Details : GP-2250 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pancreatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 26, 2019

                            Lead Product(s) : Misetionamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Translational Drug Development

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Geistlich Pharma

                            Switzerland arrow
                            AAPS
                            Not Confirmed

                            Geistlich Pharma

                            Switzerland arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Toluidine Blue

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Undisclosed

                            Recipient : University of Sao Paulo

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effects of Antimicrobial Photodynamic Therapy on Regeneration of Class II Furcation Lesions

                            Details : Toluidine Blue is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Chronic Periodontitis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 28, 2017

                            Lead Product(s) : Toluidine Blue

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Undisclosed

                            Recipient : University of Sao Paulo

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Geistlich Pharma

                            Switzerland arrow
                            AAPS
                            Not Confirmed

                            Geistlich Pharma

                            Switzerland arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Geistlich Bio-Oss

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Recipient : The Baruch Padeh Medical Center, Poriya

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Extraction of Impacted 3rd Molars, Can Bone Support of the Second Molar be Promoted by a Bio-Oss Graft?

                            Details : Geistlich Bio-Oss is a drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 27, 2016

                            Lead Product(s) : Geistlich Bio-Oss

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Recipient : The Baruch Padeh Medical Center, Poriya

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Geistlich Pharma

                            Switzerland arrow
                            AAPS
                            Not Confirmed

                            Geistlich Pharma

                            Switzerland arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Deproteinized Bovine Bone

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Phase II

                            Recipient : University of Padova, School of Dental Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Deproteinized Bovine Bone in Alveolar Bone Critical Size Defect (>2cm) Secondary to Cyst Removal

                            Details : Deproteinized Bovine Bone is a Other Large Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Maxillary Cyst.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 24, 2015

                            Lead Product(s) : Deproteinized Bovine Bone

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Phase II

                            Recipient : University of Padova, School of Dental Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Geistlich Pharma

                            Switzerland arrow
                            AAPS
                            Not Confirmed

                            Geistlich Pharma

                            Switzerland arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Taurolidine

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase I/II Study to Evaluate the Safety and Efficacy of PerioSept® as Adjunct to SRP in Subjects With Per...

                            Details : PerioSept (Taurolidine) is a Antibiotic drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Periodontitis.

                            Product Name : PerioSept

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            December 10, 2014

                            Lead Product(s) : Taurolidine

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth